Generic Name and Formulations:
Trivalent poliovirus vaccine; inactivated; whole virus grown in monkey kidney cells; IM or SC inj.
Sanofi Pasteur, Inc.
Indications for IPOL:
Poliomyelitis immunization (virus Types 1, 2, and 3).
Inject IM or SC in deltoid area. Each dose is 0.5mL. Previously unvaccinated: Two doses at a 1–2 month interval and a third dose 6–12 months later. Incompletely vaccinated: give 1–2 doses to complete series. Completely vaccinated: may give booster dose.
Inject IM or SC in midlateral thigh. Each dose is 0.5mL. Under 6 wks: not recommended. Full IPV schedule: One dose at 2 months, 4 months, 6–18 months, and 4–6 years of age. Sequential schedule with oral polio vaccine (OPV) (do not use OPV for immunocompromised patients or patients with immunocompromised household contacts): One dose of IPOL at 2 months and at 4 months of age, then 1 dose of OPV at 12–18 months and 1 dose of OPV at 4–6 years of age.
Hypersensitivity to neomycin, streptomycin, or polymyxin B. May defer in acute febrile illness.
Have epinephrine inj (1:1000) available. Immunodeficiency. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressants: may get suboptimal response.
Local irritation, fever, sleepiness, fussiness, decreased appetite.
Syringe 0.5mL (w. needle)—1, 10; Multidose vial (10 doses)—1
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Oxidized Low-Density Lipoprotein May Predict Risk for Recurrent Stroke
- Inappropriate Prescribing Protocols in Parkinson Disease
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Congress Passes Bill to Fight Opioid Crisis